NCT07114419View on ClinicalTrials.gov

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

August 1, 2026

Conditions
Obesity and Overweight
Interventions
DRUG

Efsubaglutide Alfa 20 mg QW

Efsubaglutide Alfa 20 mg QW

DRUG

Efsubaglutide Alfa 40 mg QW

Efsubaglutide Alfa 40 mg QW

DRUG

Efsubaglutide Alfa 40 mg Q2W

Efsubaglutide Alfa 40 mg Q2W

DRUG

Efsubaglutide Alfa 80 mg QW

Efsubaglutide Alfa 80 mg QW

DRUG

Efsubaglutide Alfa 80 mg Q4W

Efsubaglutide Alfa 80 mg Q4W

OTHER

Placebo

Placebo

Trial Locations (5)

Unknown

Canopy Clinical Northern Beaches, Brookvale

Canopy Clinical Sutherland Shire, Miranda

Canopy Clinical Altona North, North Altona

Fusion Clinical Research, Norwood

Canopy Clinical Wollongong, Wollongong

All Listed Sponsors
lead

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

OTHER